Novartis AG is set to acquire Regulus Therapeutics Inc. in a deal potentially worth $1.7 billion, aiming to bring innovative treatments like farabursen to patients with ADPKD, pend...
Novartis AG announces a deal to acquire Regulus Therapeutics for up to $1.7 billion, including an initial $0.8 billion payment and a contingent value right for shareholders, aiming...
Novartis AG has entered into a groundbreaking agreement to acquire Regulus Therapeutics Inc. for up to $1.7 billion, including an initial $0.8 billion payment and potential future ...
Novartis AG is set to acquire Regulus Therapeutics Inc. in a deal worth up to $1.7 billion, including an initial payment of $0.8 billion and potential future payments based on regu...
Novartis AG has entered into an agreement to acquire Regulus Therapeutics Inc. in a deal worth up to $1.7 billion, aiming to bring innovative treatments to patients with ADPKD. The...
